Latest Glioma Stories
Findings validate cancer metabolism as an approach to identify new ways to treat cancer, opens potential for new class of cancer drugs targeting metabolic enzymesAgios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may...
MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the first quarter of fiscal 2010, ended September 30, 2009. "During our first fiscal quarter, we continued to advance our lead drug nimotuzumab, which is being developed globally...
Survival rate increased by almost 4 monthsResearchers from University Hospitals Case Medical Center report promising results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a novel type of imaging called MR spectroscopy coupled with high dose radiation in the form of Gamma Knife radiosurgery.Patients' survival rates increased by almost four months (3.7 months) compared with patients who were treated with traditional conventional...
MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported additional results from a completed phase III study of nimotuzumab in children with diffuse intrinsic pontine glioma (DIPG). The updates to the preliminary data at ASCO 2008 were presented by Oncoscience AG, YM's...
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23,...
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative disorders, based in New York City, today announced that it has been awarded a Phase I grant from the National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) for the Development Of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma. The grant of up to...
SEATTLE, Oct. 22 /PRNewswire-USNewswire/ -- A major collaborative research project focused on mapping the gene activity in brain tumors was launched today. The goal of the research, known as the Ivy Glioblastoma Atlas Project (GAP), is to unlock the secrets behind one of the deadliest brain tumors known to humankind -- glioblastoma multiforme (GBM), a cancer that recently took the lives of U.S. Senator Ted Kennedy and columnist Robert Novak. The project is a partnership between the Ben and...
ANG1005 Crosses the Blood-Brain Barrier to Reduce Tumor Size and is Effective in Resistant TumorsAngiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas,...
While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height."Our findings suggest that biological factors related to energy expenditure and growth during childhood may play a role in glioma etiology. This clue could help researchers better understand important features of glioma biology and the potentially modifiable lifestyle factors...
Chemotherapy alone is just as effective as radiation / New positive prognostic factor foundInitial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Zürich showed...
